|
Krop, I; Shaffer, A L; Fearon, D T et al. (1996) The signaling activity of murine CD19 is regulated during cell development. J Immunol 157:48-56
|
|
Stanhope-Baker, P; Hudson, K M; Shaffer, A L et al. (1996) Cell type-specific chromatin structure determines the targeting of V(D)J recombinase activity in vitro. Cell 85:887-97
|
|
Kalli, K R; Fearon, D T (1994) Binding of C3b and C4b by the CR1-like site in murine CR1. J Immunol 152:2899-903
|
|
Matsumoto, A K; Martin, D R; Carter, R H et al. (1993) Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J Exp Med 178:1407-17
|
|
Tuveson, D A; Carter, R H; Soltoff, S P et al. (1993) CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science 260:986-9
|
|
Carter, R H; Fearon, D T (1992) CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256:105-7
|
|
Martin, D R; Yuryev, A; Kalli, K R et al. (1991) Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2. J Exp Med 174:1299-311
|
|
Carter, R H; Tuveson, D A; Park, D J et al. (1991) The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. J Immunol 147:3663-71
|
|
Matsumoto, A K; Kopicky-Burd, J; Carter, R H et al. (1991) Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J Exp Med 173:55-64
|
|
Kalli, K R; Hsu, P H; Bartow, T J et al. (1991) Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor. J Exp Med 174:1451-60
|
Showing the most recent 10 out of 40 publications
